Intravenous Infusions (XGHA:IIL) Net Income (Continuing Operations): GHS0.00 Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions Net Income (Continuing Operations)?

Intravenous Infusions XGHA:IIL +7.69% Net Income (Continuing Operations) is GHS0.00 Mil as of . 20.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Intravenous Infusions's Net Income (Continuing Operations) for the six months ended in . 20 was GHS0.00 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in . 20 was GHS0.00 Mil.

Intravenous Infusions  (XGHA:IIL) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Intravenous Infusions Net Income (Continuing Operations) Related Terms

Intravenous Infusions Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions Net Income (Continuing Operations) Chart

Intravenous Infusions Annual Data
Trend
Net Income (Continuing Operations)

Intravenous Infusions Semi-Annual Data
Net Income (Continuing Operations)

Intravenous Infusions Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in . 20 was GHS0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of GHS0.00 Mil mean?
Intravenous Infusions (XGHA:IIL) has a Net Income (Continuing Operations) of GHS0.00 Mil as of . 20. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Intravenous Infusions and its competitors.
Is Intravenous Infusions' Net Income (Continuing Operations) too high?
Intravenous Infusions' current Net Income (Continuing Operations) is GHS0.00 Mil.
How does Intravenous Infusions' Net Income (Continuing Operations) compare to PTLF and PCYN?
Intravenous Infusions' Net Income (Continuing Operations) of GHS0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Intravenous Infusions and its competitors. Intravenous Infusions's current Net Income (Continuing Operations) is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Net Income (Continuing Operations) of GHS0.00 Mil. The current Net Income (Continuing Operations) is GHS0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Net Income (Continuing Operations) is GHS0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.